Caesar Rivise’s Diversity Shines Through in Victory for Generic Drug Manufacturers
Posted on Oct 18, 2018 in News
In an important victory for consumers, Judge Sheridan of the United States District Court for the District of New Jersey on October 12, 2018 issued an order invalidating U.S. Patents Nos. 8,673,927 and 9,173,859 for obviousness and obviousness-type double patenting. The patents invalidated in this Hatch-Waxman litigation relate to methods of using the type II diabetes medications Tradjenta® and Jentadueto®.
The victory followed a two-week trial held in the Trenton, New Jersey courthouse. Key to this victory was the work of Caesar Rivise’s team of Robert S. Silver, Lynn M. Terrebonne, Ph.D., Salvatore R. Guerriero and Pei-Ru Wey, Pharm. D.
Lynn Terrebonne, a pharmacologist, spearheaded the direct and cross examination of the medical invalidity experts. Pei-Ru Wey, a pharmacist, and Sal Guerriero took lead on attacking the commercial success of the branded products with Ms. Wey conducting the cross-examination of the plaintiffs’ economics expert.